484 related articles for article (PubMed ID: 21228246)
21. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
22. Insulin glargine dosing before next-day surgery: comparing three strategies.
Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
[TBL] [Abstract][Full Text] [Related]
23. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
24. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
[TBL] [Abstract][Full Text] [Related]
25. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
26. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
[TBL] [Abstract][Full Text] [Related]
28. Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy.
Gosmanov AR; Goorha S; Stelts S; Peng L; Umpierrez GE
Endocr Pract; 2013; 19(2):231-5. PubMed ID: 23337144
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non-inferiority randomized trial.
Kuchay MS; Mathew A; Mishra M; Surendran P; Kaur P; Wasir JS; Gill HK; Jain R; Gagneja S; Kohli C; Kumari P; Singh MK; Mishra SK
Diabet Med; 2023 Jan; 40(1):e15002. PubMed ID: 36354383
[TBL] [Abstract][Full Text] [Related]
30. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
31. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
32. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study.
Raccah D; Haak TJ; Huet D; Monnier L; Robertson D; Labard P; Soler J; Penfornis A
Diabetes Metab; 2012 Dec; 38(6):507-14. PubMed ID: 23116646
[TBL] [Abstract][Full Text] [Related]
33. Basal-bolus insulin versus sliding-scale insulin for inpatient glycaemic control: a clinical practice comparison.
Roberts GW; Aguilar-Loza N; Esterman A; Burt MG; Stranks SN
Med J Aust; 2012 Mar; 196(4):266-9. PubMed ID: 22409694
[TBL] [Abstract][Full Text] [Related]
34. The GesTIO protocol experience: safety of a standardized order set for subcutaneous insulin regimen in elderly hospitalized patients.
Franchin A; Maran A; Bruttomesso D; Corradin ML; Rossi F; Zanatta F; Barbato GM; Sicolo N; Manzato E
Aging Clin Exp Res; 2017 Dec; 29(6):1087-1093. PubMed ID: 28238154
[TBL] [Abstract][Full Text] [Related]
35. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study.
Meyer C; Boron A; Plummer E; Voltchenok M; Vedda R
Diabetes Care; 2010 Dec; 33(12):2496-501. PubMed ID: 20805258
[TBL] [Abstract][Full Text] [Related]
36. [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective].
Jermendy G; Kovács G
Orv Hetil; 2018 Dec; 159(50):2122-2128. PubMed ID: 30545262
[TBL] [Abstract][Full Text] [Related]
37. Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial).
Kuchay MS; Khatana P; Mishra M; Surendran P; Kaur P; Wasir JS; Gill HK; Singh A; Jain R; Kohli C; Bakshi G; Radhika V; Saheer S; Singh MK; Mishra SK
Acta Diabetol; 2023 Nov; 60(11):1481-1490. PubMed ID: 37380728
[TBL] [Abstract][Full Text] [Related]
38. Real-world community hospital hyperglycemia management in noncritically ill, type 2 diabetic patients: a comparison between basal-bolus insulin and correctional insulin.
Yang CJ; Bourgeois C; Delgado E; Graham W; Burmeister MA
J Pharm Pharm Sci; 2024; 27():13074. PubMed ID: 38919469
[TBL] [Abstract][Full Text] [Related]
39. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
Mathur SK; Bansal A; Khan ZY
J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
[TBL] [Abstract][Full Text] [Related]
40. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
